{"title":"布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的现实世界治疗模式在社区肿瘤学设置。","authors":"Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang","doi":"10.1080/14796694.2025.2554354","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.</p><p><strong>Materials & methods: </strong>A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.</p><p><strong>Results: </strong>402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; <i>P</i> < 0.01) and displayed significantly higher adherence to treatment.</p><p><strong>Conclusions: </strong>In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3043-3049"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490371/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.\",\"authors\":\"Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang\",\"doi\":\"10.1080/14796694.2025.2554354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.</p><p><strong>Materials & methods: </strong>A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.</p><p><strong>Results: </strong>402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; <i>P</i> < 0.01) and displayed significantly higher adherence to treatment.</p><p><strong>Conclusions: </strong>In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"3043-3049\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490371/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2554354\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2554354","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.
Materials & methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.
Results: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.
Conclusions: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
